Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a new clinical trial agreement for the CHM 1101 Phase 1B clinical trial in glioblastoma at the Sarah Cannon Transplant and Cellular Therapy Program at St David's South Austin Medical Center in the US.
The company said the trial would build upon the promising early outcomes seen in the ongoing CHM 1101 Phase 1A clinical trial at City of Hope.
It said outcomes from the initial two dose levels of the Phase 1A trial had been previously presented and demonstrated patient safety with a disease stability rate of approximately 70 per cent.
"We are very pleased to begin a clinical collaboration with SCRI, a leading clinical research organisation that serves communities across 24 states," said Jason Litten, the chief medical officer of Chimeric Therapeutics.
"With the integrated oncology research network of SCRI, we believe that this collaboration will enable us to rapidly advance our clinical development plan to gain an understanding of the potential benefit of CHM 1101 in patients with Glioblastoma."
"With more than 300,000 new cases diagnosed globally and over 250,000 deaths each year, researching innovative treatment options for patients with Glioblastoma is critical," said Dr Aravind Ramakrishnan, investigator, SCRI, and Medical Director at the Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center. "We look forward to collaborating with Chimeric to explore the potential of next-generation CAR T cell therapies for these patients."
